Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 10—October 2011
Dispatch

Extensively Drug-Resistant Tuberculosis in Women, KwaZulu-Natal, South Africa

Author affiliations: Albert Einstein College of Medicine, Bronx, New York, USA (M.R. O’Donnell); Centre for AIDS Programme of Research in South Africa, Durban, South Africa (M.R. O’Donnell, L. Werner, N. Padayatchi); Touro College Graduate School of Social Work, New York, New York, USA (J. Zelnick); King George V Hospital, Sydenham, South Africa (I. Master); Medical Research Council, Cape Town, South Africa (M. Loveday); Boston University School of Public Health, Boston, Massachusetts, USA (C.R. Horsburgh)

Cite This Article

Abstract

To determine whether women in KwaZulu-Natal, South Africa, with drug-resistant tuberculosis (TB) were more likely than men to have extensively drug-resistant TB, we reviewed 4,514 adults admitted during 2003–2008 for drug-resistant TB. Female sex independently predicted extensively drug-resistant TB, even after we controlled for HIV infection. This association needs further study.

Tuberculosis (TB) remains a leading infectious cause of death worldwide (1), especially where HIV is endemic (2). In industrialized countries, outbreaks of drug-resistant TB (multidrug-resistant [MDR] and extensively drug-resistant [XDR] TB) have occurred predominantly among male patients (1). However, in South Africa, where TB and HIV are endemic, aggregate data suggest that a greater proportion of women than men with TB have MDR TB (3).

In South Africa, HIV infection is more prevalent among women than men. Nationally, women 25–29 years of age have the highest (32.7%) HIV prevalence; for men, prevalence peaks at age 30–34 years (25.8%) (4). KwaZulu-Natal Province, the epicenter of the HIV/AIDS epidemic in South Africa, has a high incidence of hospital admissions for MDR TB and XDR TB and >70% HIV co-infection among MDR TB patients (5). Since 2003, fueled by a generalized HIV epidemic, TB incidence in South Africa (1) and hospital admissions for MDR TB in KwaZulu-Natal have doubled (5). Observational studies of MDR TB and XDR TB in South Africa report higher proportions of female patients with MDR TB or XDR TB (69). We conducted this study to determine whether women in KwaZulu-Natal with drug-resistant TB were more likely than men to have XDR TB, even after we controlled for HIV and other factors.

The Study

The study design has been described (5). Briefly, we retrospectively reviewed adult MDR TB and XDR TB patients admitted during 2003–2008 for treatment initiation to King George V Hospital (KGVH), a public TB-referral hospital in KwaZulu-Natal. Admitting physicians and staff collected data routinely. During the study period, KGVH was the only public hospital in the province authorized to initiate treatment for MDR TB and XDR TB, and all therapy was initiated on an inpatient basis.

All patients >18 years of age who had culture-confirmed MDR TB or XDR TB with standard drug susceptibility testing were included. Repeat admissions were excluded. MDR TB and XDR TB were defined according to standard definitions (10). Ethics review committees at the University of KwaZulu-Natal and Boston University (Boston, MA, USA) approved the study protocol.

We used Fisher exact or χ2 tests to compare categorical variables. Medians were compared by using the Wilcoxon-Mann-Whitney U test. Univariate and multivariate logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Statistically significant variables or variables that caused >10% change in the univariate OR were included in the multivariate model. Interaction terms were assessed by using Wald tests, with p<0.2 considered significant. Test for trend was performed by using the Cochran-Armitage test. Analysis was performed with SAS version 9.3 software (SAS Institute, Inc., Cary, NC, USA).

Figure

Thumbnail of Flow diagram for patients with multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) admitted to King George V Hospital, KwaZulu-Natal, South Africa, 2003–2008.

Figure. Flow diagram for patients with multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) admitted to King George V Hospital, KwaZulu-Natal, South Africa, 2003–2008.

A total of 4,941 patients with MDR TB or XDR TB from throughout KwaZulu-Natal were admitted for initiation of drug-resistant TB treatment to KGVH during the study period (Figure). Among 4,514 eligible patients with MDR TB or XDR TB, women were younger (median age [interquartile range] 32 [26–39] vs. 36 [30–44] years), more likely to be HIV infected (65% vs. 47%), and more likely than men to be receiving antiretroviral therapy (ART) (51% vs. 43%) (Table 1). Women with drug-resistant TB were more likely than men with drug-resistant TB to have XDR TB (p<0.0001).

On univariate analysis, HIV status, ART (among HIV-infected), female gender, previous TB treatment, and year of admission to KGVH were significantly associated with XDR TB (Table 2). On multivariate analysis, only female gender (OR 1.38, 95% CI 1.11–1.73), previous TB treatment (OR 2.16, 95% CI 1.09–4.28), and year of admission were independently associated with XDR TB. In the HIV strata, ART was not significantly associated with XDR TB after adjustment was made for confounding variables. Confounding of ART and XDR TB by year of admission among HIV co-infected persons most likely resulted from increased XDR TB case finding after a highly publicized XDR TB outbreak in 2006 and increased ART use after public health rollout of ART in KwaZulu-Natal in 2004. The interaction terms HIV × gender, gender × age (categorical), and health care worker (HCW) × gender were not significantly associated with XDR TB.

Most (59%) patients admitted with XDR TB were women, which did not change significantly during the study period (test for trend p = 0.68). For MDR TB, the data showed increasingly more female MDR TB patients admitted over the study period (p<0.001) (Table A1).

Conclusions

Our major finding was that women admitted with drug-resistant TB to KGVH were 38% more likely than men to have XDR TB. This association remained significant after adjustment for potential confounding variables, including HIV status. Temporal analysis showed persistently more women with XDR TB and increasing proportions of women with MDR TB during the study period. Together these data support the notion that the epidemic of drug-resistant TB predominantly affects women in KwaZulu-Natal.

Supporting context comes from observational studies of drug-resistant TB in South Africa. In South African studies, higher percentages of XDR TB (50%–56%) than MDR TB patients (43%–53%) are women (69). However, studies from low-prevalence HIV settings report fewer women with drug-resistant TB. In a study in the United States, few patients with MDR TB (36%) or XDR TB (38%) were female (11). Similarly, in cohorts from Latvia, Peru, and Russia, lower percentages of patients with MDR TB (17%–40%) and XDR TB (29%–35%) were female (1214). Gender differences in drug-resistant TB in areas of HIV endemicity and low prevalence suggest a possible effect of the AIDS epidemic on prevalence of drug-resistant TB in women.

Our study has several limitations. We lacked details about hospital admission and factors associated with referral. Women with XDR TB might have been preferentially referred compared with men with XDR TB, women with MDR TB, or both. We lacked data on HIV factors, such as CD4 T-cell counts, ART adherence, and viral load. Similarly, we lacked data on previous TB treatment, medications, adherence, and outcome. Finally, as a hospital-based retrospective study, factors associated with survival to hospital admission, decisions to seek care, and referral patterns may introduce bias.

Potential causes of the association between female gender and XDR TB are not known. HIV-related factors could explain the association of XDR TB and female gender. For example, women with drug-resistant TB may be more adherent to ART, leading to improved survival, and therefore increased time for XDR TB to develop. Factors associated with secondary development of XDR TB, such as TB medication adherence or previous MDR TB treatment, could explain the association between XDR TB and female gender (15). Factors associated with exposure to drug-resistant TB strains, including location and duration of exposure, could explain the association of XDR TB and female gender. For example, women are more likely to participate in formal and informal care work, with potential exposure to drug-resistant TB strains, and therefore primary XDR TB might be more likely to develop (5).

These results may have major policy implications for TB control in KwaZulu-Natal and South Africa. Because women are more likely to have XDR TB in KwaZulu-Natal, efforts should be made to develop gender-sensitive interventions to improve diagnosis, treatment, and prevention for drug-resistant TB and HIV. Decentralization of drug-resistant TB treatment may better accommodate women in conjunction with their work, family, and child-rearing responsibilities. Further studies are needed to confirm the magnitude and determinants of the association between female gender and XDR TB.

Dr O’Donnell is an assistant professor of pulmonary medicine at the Albert Einstein College of Medicine in the Bronx, New York, and a research associate at the Centre for AIDS Programme of Research in South Africa, Durban, South Africa. His research focuses on improving treatment outcomes of drug-resistant TB and HIV in South Africa through epidemiologic, clinical, and translational studies.

Top

Acknowledgment

M.R.O. was supported by the National Institutes of Health (NIH) F32 AI52074 (National Institute for Allergy and Infectious Diseases), and an American Thoracic Society Fellows Career Development Award. M.R.O. and N.P. were supported by the Centre for AIDS Programme of Research, which was established by NIH and US Department of Health and Human Services (grant no. A1069469). N.P. also was supported by Columbia University–Southern African Fogarty AIDS International Training and Research Program, funded by the Fogarty International Center, NIH (grant no. D43TW00231).

Top

References

  1. World Health Organization. Global tuberculosis control—surveillance, planning, financing. Geneva: The Organization; 2010.
  2. Chaisson  RE, Martinson  NA. Tuberculosis in Africa—combating an HIV-driven crisis. N Engl J Med. 2008;358:108992. DOIPubMedGoogle Scholar
  3. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: The Organization; 2010.
  4. Shisana  O, Rehle  T, Simbayi  LC, Zuma  K, Jooste  S, Pillay-van-Wyk  V, South African national HIV prevalence, incidence, behaviour and communication survey 2008: a turning tide among teenagers? Cape Town (South Africa): HSRC Press; 2009.
  5. O’Donnell  MR, Jarand  J, Loveday  M, Padayatchi  N, Zelnick  J, Werner  L, High incidence of hospital admissions with multidrug resistant and extensively drug resistant tuberculosis among South African health care workers. Ann Intern Med. 2010;153:51622.PubMedGoogle Scholar
  6. O’Donnell  MR, Padayatchi  N, Master  I, Osburn  G, Horsburgh  CR. Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis. 2009;13:85561.PubMedGoogle Scholar
  7. Gandhi  NR, Shah  NS, Andrews  JR, Vella  V, Moll  AP, Scott  M, HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:806. DOIPubMedGoogle Scholar
  8. Dheda  K, Shean  K, Zumla  A, Badri  M, Streicher  EM, Page-Shipp  L, Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798807. DOIPubMedGoogle Scholar
  9. Heller  T, Lessells  RJ, Wallrauch  CG, Bärnighausen  T, Cooke  GS, Mhlongo  L, Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2010;14:4206.PubMedGoogle Scholar
  10. Centers for Disease Control and Prevention. Notice to readers. Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep. 2006;55:1176.
  11. Shah  NS, Pratt  R, Armstrong  L, Robison  V, Castro  KG, Cegielski  JP. Extensively drug-resistant tuberculosis in the United States, 1993–2007. JAMA. 2008;300:215360. DOIPubMedGoogle Scholar
  12. Mitnick  CD, Shin  SS, Seung  KJ, Rich  ML, Atwood  SS, Furin  JJ, Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359:56374. DOIPubMedGoogle Scholar
  13. Leimane  V, Dravniece  G, Riekstina  V, Sture  I, Kammerer  S, Chen  MP, Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur Respir J. 2010;36:58493. DOIPubMedGoogle Scholar
  14. Shin  SS, Pasechnikov  AD, Gelmanova  IY, Peremitin  GG, Strelis  AK, Mishustin  S, Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10:4028.PubMedGoogle Scholar
  15. Cox  HS, Sibilia  K, Feuerriegel  S, Kalon  S, Polonsky  J, Khamraev  AK, Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med. 2008;359:2398400. DOIPubMedGoogle Scholar

Top

Figure
Tables

Top

Cite This Article

DOI: 10.3201/eid1710.110105

Table of Contents – Volume 17, Number 10—October 2011

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Max R. O’Donnell, Division of Pulmonary Medicine. Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA

Send To

10000 character(s) remaining.

Top

Page created: September 26, 2011
Page updated: September 26, 2011
Page reviewed: September 26, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external